Lifesci Capital Predicts Immunome FY2024 Earnings
Equities research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for shares of Immunome in a note issued to investors on Tuesday, March 11th. Lifesci Capital ...
LifeSci Capital Initiates a Buy Rating on Zymeworks (ZYME)
LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...
Protara Therapeutics (TARA) Has a New Rating from LifeSci Capital
In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Protara Therapeutics (TARA – Research ...